Should I buy or sell Zentalis Pharmaceuticals stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ZNTL shares. View ZNTL analyst ratings or view top-rated stocks .

What is Zentalis Pharmaceuticals' stock price target for 2024?

7 equities research analysts have issued 12 month price targets for Zentalis Pharmaceuticals' stock. Their ZNTL share price targets range from $15.00 to $70.00. On average, they anticipate the company's stock price to reach $38.57 in the next year. This suggests a possible upside of 207.6% from the stock's current price. View analysts price targets for ZNTL or view top-rated stocks among Wall Street analysts .

How have ZNTL shares performed in 2024?

Zentalis Pharmaceuticals' stock was trading at $15.15 at the start of the year. Since then, ZNTL stock has decreased by 17.2% and is now trading at $12.54. View the best growth stocks for 2024 here .

When is Zentalis Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our ZNTL earnings forecast .

How were Zentalis Pharmaceuticals' earnings last quarter?

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.09.

What ETF holds Zentalis Pharmaceuticals' stock?

Range Cancer Therapeutics ETF holds 5,026 shares of ZNTL stock, representing 1.32% of its portfolio.

What other stocks do shareholders of Zentalis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR) , Zogenix (ZGNX) , AbbVie (ABBV) , Advanced Micro Devices (AMD) , BioMarin Pharmaceutical (BMRN) , Bristol-Myers Squibb (BMY) , Clovis Oncology (CLVS) , Johnson & Johnson (JNJ) , Merck & Co., Inc. (MRK) and Phillips 66 (PSX) .

When did Zentalis Pharmaceuticals IPO?

Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.

Who are Zentalis Pharmaceuticals' major shareholders?

Zentalis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Wealth Enhancement Advisory Services LLC (0.06%) and Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Alexis Pinto , Anthony Y Sun , Cam Gallagher , Carrie Brownstein, David Michael Johnson , Dimitris Voliotis , Jan Skvarka, Kevin D Bunker, Kevin D Bunker , Kimberly Blackwell , Matrix Capital Management Comp and Melissa B Epperly . View institutional ownership trends .

How do I buy shares of Zentalis Pharmaceuticals?

Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:ZNTL

Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis

→ This consistently signaled gains of 453%... 610%... and even 1036%... (From Insiders Exposed) (Ad)

Buy ZNTL with Qtrade

Free ZNTL Stock Alerts

$12.54

-0.17 (-1.34%)

(As of 04/18/2024 ET)

Compare

Today's Range: $12.50
▼
$12.94
50-Day Range: $10.83
▼
$16.13
52-Week Range: $9.56
▼
$31.46

Volume: 678,124 shs
Average Volume: 803,960 shs
Market Capitalization: $889.84 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $38.57

Get Zentalis Pharmaceuticals alerts:

Zentalis Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 207.6% Upside
$38.57 Price Target
Short Interest: Bearish
21.89% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.54
Based on 5 Articles This Week
Insider Trading: Selling Shares
$42,854 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($3.72) to ($3.78) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.91 out of 5 stars

Medical Sector

809th out of 918 stocks

Pharmaceutical Preparations Industry

356th out of 402 stocks

3.3

Analyst's Opinion

Consensus Rating
Zentalis Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Amount of Analyst Coverage
Zentalis Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
21.89% of the outstanding shares of Zentalis Pharmaceuticals have been sold short.
Short Interest Ratio / Days to Cover
Zentalis Pharmaceuticals has a short interest ratio ("days to cover") of 19.1, which indicates bearish sentiment.
Change versus previous month
Short interest in Zentalis Pharmaceuticals has recently decreased by 7.23%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Zentalis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Zentalis Pharmaceuticals does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ZNTL.

2.0

News and Social Media Coverage

News Sentiment
Zentalis Pharmaceuticals has a news sentiment score of 0.54. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.
News Coverage This Week
MarketBeat has tracked 5 news articles for Zentalis Pharmaceuticals this week, compared to 2 articles on an average week.
MarketBeat Follows
Only 1 people have added Zentalis Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

0.8

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Zentalis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $42,854.00 in company stock.
Percentage Held by Insiders
Only 6.10% of the stock of Zentalis Pharmaceuticals is held by insiders.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Zentalis Pharmaceuticals are expected to decrease in the coming year, from ($3.72) to ($3.78) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Zentalis Pharmaceuticals is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Zentalis Pharmaceuticals is -2.76, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Zentalis Pharmaceuticals has a P/B Ratio of 2.03. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

AI “wealth window” is closing soon!

Today, I’m making my boldest prediction ever. Next-generation AI technology will create the first $100 TRILLION industry.

I put together this personal video [HERE]…

About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)

Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer. The company's products pipeline also includes ZN-d5, an oral small molecule inhibitor of B-cell lymphoma 2, for hematological malignancies and related disorders; and BCL-xL heterobifunctional degrader, a member of the anti-apoptotic BCL-2 proteins, for solid tumors and hematological malignancies. Zentalis Pharmaceuticals, Inc. has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC; Pfizer, Inc.; Zentera Therapeutics; Dana-Farber; and GlaxoSmithKline plc. The company was incorporated in 2014 and is headquartered in New York, New York.

ZNTL Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ZNTL Stock News Headlines

April 18, 2024 | americanbankingnews.com

Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) Given Consensus Recommendation of "Moderate Buy" by Brokerages

April 13, 2024 | investing.com

Zentalis Pharmaceuticals CFO Melissa Epperly steps down

April 18, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

Eager to enhance your investment strategies with foresight? Dive into our intriguing report: "The Top 3 AI Stocks for 2024." Gain profound insights and uncover the secrets with just a click! Why This Report Is Your Gateway to Success: * Expertly Curated: Delve into the AI stocks handpicked by our market analysts for 2024's success story. * In-Depth Analysis: Dive deep into comprehensive profiles and explore each top stock. (**By clicking the link you are subscribing to The Wealthiest Investor Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy. Full disclosures found here.)

April 13, 2024 | americanbankingnews.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Shares Gap Down to $14.73

April 12, 2024 | seekingalpha.com

Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling

April 12, 2024 | americanbankingnews.com

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price Down 7.7%

April 11, 2024 | marketwatch.com

Zentalis Shares Fall After Chief Financial Officer Resigns

April 10, 2024 | investing.com

Zentalis Pharmaceuticals Llc (ZNTL)

April 18, 2024 | Darwin (Ad)

Explore the Future: Unlock the Top 3 AI Stocks for 2024 Report

April 2, 2024 | globenewswire.com

Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024

April 1, 2024 | globenewswire.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 11, 2024 | finance.yahoo.com

ZNTL Jul 2024 12.500 call

March 10, 2024 | finance.yahoo.com

ZNTL Jul 2024 10.000 call

March 1, 2024 | globenewswire.com

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

February 29, 2024 | edition.cnn.com

Zentalis Pharmaceuticals, Inc.

February 29, 2024 | markets.businessinsider.com

Buy Rating on Zentalis Pharmaceuticals Amidst Undervalued Share Price and Promising Clinical Developments

February 29, 2024 | finance.yahoo.com

Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Intrinsic Value Is Potentially 98% Above Its Share Price

February 28, 2024 | markets.businessinsider.com

Buy Rating Affirmed for Zentalis Pharmaceuticals on Strategic Positioning and Clinical Prospects in Ovarian Cancer Treatment

February 28, 2024 | markets.businessinsider.com

Oppenheimer Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

February 28, 2024 | globenewswire.com

Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences

February 28, 2024 | markets.businessinsider.com

TD Cowen Keeps Their Buy Rating on Zentalis Pharmaceuticals (ZNTL)

February 27, 2024 | finance.yahoo.com

Zentalis Pharmaceuticals Inc (ZNTL) Reports Full Year 2023 Financial Results and Provides ...

February 27, 2024 | globenewswire.com

Zentalis Pharmaceuticals Reports Full Year 2023 Financial Results and Operational Updates

February 20, 2024 | msn.com

RAPT stock craters after FDA puts clinical hold on dermatitis drug

February 14, 2024 | finance.yahoo.com

Down -19.06% in 4 Weeks, Here's Why You Should You Buy the Dip in Zentalis Pharmaceuticals, Inc. (ZNTL)

February 13, 2024 | morningstar.com

Zentalis Pharmaceuticals Inc Ordinary Shares

February 13, 2024 | finance.yahoo.com

Zentalis Pharmaceuticals to Participate in the Oppenheimer Healthcare Life Sciences Conference

See More Headlines

Receive ZNTL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Zentalis Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/27/2024
Today: 4/18/2024
Next Earnings (Estimated): 5/08/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:ZNTL
CUSIP: N/A
CIK: 1725160
Web: www.zentalis.com
Phone: 212-433-3791
Fax: N/A
Employees: 124
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $38.57
High Stock Price Target: $70.00
Low Stock Price Target: $15.00
Potential Upside/Downside: +207.6%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($4.54)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-292,190,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -63.93%
Return on Assets: -51.99%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 7.16
Quick Ratio: 7.16

Sales & Book Value

Annual Sales: N/A
Price / Sales: N/A
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.18 per share
Price / Book: 2.03

Miscellaneous

Outstanding Shares: 70,960,000
Free Float: 66,631,000
Market Cap: $889.84 million
Optionable: Optionable
Beta: 1.73

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Kimberly Lynn Blackwell M.D. (Age 54)
CEO & Director
Comp: $1.12M
Mr. Cameron S. Gallagher M.B.A. (Age 53)
Co-Founder, President & Director
Comp: $767.69k
Ms. Melissa B. Epperly M.B.A. (Age 45)
CFO & Treasurer
Comp: $721.64k
Ms. Andrea Paul J.D. (Age 42)
Chief Legal Officer & Corporate Secretary
Comp: $668.2k
Dr. Mark Lackner Ph.D. (Age 56)
Chief Scientific Officer
Dr. Diana F. Hausman M.D. (Age 61)
Chief Medical Officer & Director
Ms. Kimberly Freeman
Chief Strategy Officer
Dr. Kyle Rasbach Ph.D. (Age 44)
Pharm.D., Chief Business Officer
Dr. Adrian Jubb M.D.
Ph.D., Executive Vice President of Clinical Development

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ZNTL Stock Analysis - Frequently Asked Questions

Should I buy or sell Zentalis Pharmaceuticals stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Zentalis Pharmaceuticals in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ZNTL shares.
View ZNTL analyst ratings or view top-rated stocks.
What is Zentalis Pharmaceuticals' stock price target for 2024?: 7 equities research analysts have issued 12 month price targets for Zentalis Pharmaceuticals' stock. Their ZNTL share price targets range from $15.00 to $70.00. On average, they anticipate the company's stock price to reach $38.57 in the next year. This suggests a possible upside of 207.6% from the stock's current price.
View analysts price targets for ZNTL or view top-rated stocks among Wall Street analysts.
How have ZNTL shares performed in 2024?: Zentalis Pharmaceuticals' stock was trading at $15.15 at the start of the year. Since then, ZNTL stock has decreased by 17.2% and is now trading at $12.54.
View the best growth stocks for 2024 here.
When is Zentalis Pharmaceuticals' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our ZNTL earnings forecast.
How were Zentalis Pharmaceuticals' earnings last quarter?: Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) announced its quarterly earnings results on Tuesday, February, 27th. The company reported ($0.83) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.92) by $0.09.
What ETF holds Zentalis Pharmaceuticals' stock?: Range Cancer Therapeutics ETF holds 5,026 shares of ZNTL stock, representing 1.32% of its portfolio.

What other stocks do shareholders of Zentalis Pharmaceuticals own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Zentalis Pharmaceuticals investors own include Esperion Therapeutics (ESPR), Zogenix (ZGNX), AbbVie (ABBV), Advanced Micro Devices (AMD), BioMarin Pharmaceutical (BMRN), Bristol-Myers Squibb (BMY), Clovis Oncology (CLVS), Johnson & Johnson (JNJ), Merck & Co., Inc. (MRK) and Phillips 66 (PSX).
When did Zentalis Pharmaceuticals IPO?: Zentalis Pharmaceuticals (ZNTL) raised $131 million in an initial public offering on Friday, April 3rd 2020. The company issued 7,700,000 shares at a price of $16.00-$18.00 per share. Morgan Stanley, Jefferies, SVB Leerink and Guggenheim Securities acted as the underwriters for the IPO.
Who are Zentalis Pharmaceuticals' major shareholders?: Zentalis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional investors include Wealth Enhancement Advisory Services LLC (0.06%) and Los Angeles Capital Management LLC (0.05%). Insiders that own company stock include Alexis Pinto, Anthony Y Sun, Cam Gallagher, Carrie Brownstein, David Michael Johnson, Dimitris Voliotis, Jan Skvarka, Kevin D Bunker, Kevin D Bunker, Kimberly Blackwell, Matrix Capital Management Comp and Melissa B Epperly.
View institutional ownership trends.
How do I buy shares of Zentalis Pharmaceuticals?: Shares of ZNTL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:ZNTL) was last updated on 4/18/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Zentalis Pharmaceuticals (ZNTL) Stock Price, News & Analysis

Zentalis Pharmaceuticals MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

News and Social Media Coverage

News Sentiment

News Coverage This Week

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Zentalis Pharmaceuticals Stock (NASDAQ:ZNTL)

ZNTL Stock Price History

ZNTL Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

ZNTL Stock Analysis - Frequently Asked Questions

Overall MarketRank^™